| Drug Type Small molecule drug | 
| Synonyms 2-(N-Benzylanilinomethyl)-2-imidazoline, 2-(N-Phenyl-N-benzylaminomethyl)imidazoline, 4,5-Dihydro-N-phenyl-N-phenylmethyl-1H-imidazole-2-methanamine + [2] | 
| Target | 
| Action antagonists | 
| Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC17H20ClN3 | 
| InChIKeySWKDMSRRIBZZAY-UHFFFAOYSA-N | 
| CAS Registry2508-72-7 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| D07459 | Antazoline Hydrochloride | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Arrhythmias, Cardiac | China  | - | |
| Hypersensitivity | China  | - | 
| Phase 4 | 74 | xkprpdbbsx(dbkqmmxmgd) = lksgzgodqo yxtuamiqdh (vbglrbdpbh ) | Positive | 01 Oct 2017 | |||
| Placebo | xkprpdbbsx(dbkqmmxmgd) = ryllxrgeuo yxtuamiqdh (vbglrbdpbh ) | 





